IBM Retirement Fund boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 15.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,438 shares of the medical instruments supplier’s stock after purchasing an additional 861 shares during the quarter. IBM Retirement Fund’s holdings in Becton Dickinson and were worth $1,511,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Sii Investments Inc. WI raised its stake in shares of Becton Dickinson and by 2.2% in the 2nd quarter. Sii Investments Inc. WI now owns 1,738 shares of the medical instruments supplier’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Becton Dickinson and by 0.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 9,960 shares of the medical instruments supplier’s stock valued at $1,925,000 after buying an additional 45 shares in the last quarter. WFG Advisors LP raised its stake in shares of Becton Dickinson and by 0.9% in the 2nd quarter. WFG Advisors LP now owns 5,376 shares of the medical instruments supplier’s stock valued at $1,049,000 after buying an additional 48 shares in the last quarter. Aureus Asset Management LLC raised its stake in shares of Becton Dickinson and by 5.6% in the 2nd quarter. Aureus Asset Management LLC now owns 1,695 shares of the medical instruments supplier’s stock valued at $331,000 after buying an additional 90 shares in the last quarter. Finally, Quantum Capital Management raised its stake in shares of Becton Dickinson and by 7.3% in the 2nd quarter. Quantum Capital Management now owns 1,499 shares of the medical instruments supplier’s stock valued at $292,000 after buying an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 75.56% of the company’s stock.

In related news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.00% of the company’s stock.

Shares of Becton Dickinson and Co (NYSE BDX) opened at $218.89 on Tuesday. The stock has a market cap of $57,811.89, a PE ratio of 22.52, a P/E/G ratio of 1.49 and a beta of 1.12. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $2.33 EPS. analysts expect that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Piper Jaffray Companies restated an “overweight” rating and issued a $260.00 price objective (up previously from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research note on Wednesday, January 3rd. Evercore ISI assumed coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price objective for the company. Finally, Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the company a “buy” rating in a research note on Friday, December 29th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $237.27.

ILLEGAL ACTIVITY WARNING: “Becton Dickinson and Co (BDX) Shares Bought by IBM Retirement Fund” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/13/becton-dickinson-and-co-bdx-shares-bought-by-ibm-retirement-fund.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.